Compare Davita Inc (DVA) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Davita Inc trades at $178.35 (market cap $11.38B), while State Street Technology Select Sector SPDR ETF trades at $188.55. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | XLK | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Sector/Thematic |
52-Week High | $240.96 | $198.21 |
52-Week Low | $103.87 | $127.49 |
Enterprise Value | $24.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.
The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.
XLK trades at $189.38, up 1.64% with strong technical momentum as moving averages signal bullish conditions. The Technology Select Sector SPDR Fund shows institutional interest with record sector ETF inflows of $25 billion in July 2026 (ETF Trends, 2026-08-10). Recent earnings strength from holdings like Microsoft supports the fund's performance, though RSI levels suggest potential near-term overbought conditions.
Outlook remains positive given sector earnings growth and AI-driven momentum, but risks include concentration in mega-cap stocks and valuation concerns. The fund's heavy reliance on top holdings creates sensitivity to individual company performance, requiring careful monitoring of diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
